Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes

Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells

(2018) Chunwan Lu et al.   BMC CANCER

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models

(2018) Robert D. Leone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells

(2018) Wei Xiao et al.   JOURNAL OF IMMUNOLOGY

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells

(2018) Luciano Castiello et al.   Cancer Immunology Research

H3K4me3 mediates the NF-κB p50 homodimer binding to the pdcd1 promoter to activate PD-1 transcription in T cells

(2018) Priscilla S. Redd et al.   OncoImmunology

PIP5 Kinases Regulate Membrane Phosphoinositide and Actin Composition for Targeted Granule Secretion by Cytotoxic Lymphocytes

(2018) Christian M. Gawden-Bone et al.   IMMUNITY

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

(2017) Meredith L. Stone et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs

(2017) Michael C. Brown et al.   Science Translational Medicine

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

(2017) Anje Cauwels et al.   OncoImmunology

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Temporally Programmed CD8α + DC Activation Enhances Combination Cancer Immunotherapy

(2016) Alice Tzeng et al.   Cell Reports

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses

(2016) Takumi Kumai et al.   Cancer Immunology Research

The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells

(2016) Chunwan Lu et al.   OncoImmunology

Combinatorial Immunotherapy of Polyinosinic–Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors

(2014) Toshihiro Nagato et al.   CLINICAL CANCER RESEARCH

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response

(2013) Giovanna Schiavoni et al.   Frontiers in Immunology

Direct Effects of Type I Interferons on Cells of the Immune System

(2011) S. Hervas-Stubbs et al.   CLINICAL CANCER RESEARCH

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CD4 and CD8 T Cell Immune Activation during Chronic HIV Infection: Roles of Homeostasis, HIV, Type I IFN, and IL-7

(2011) M. Catalfamo et al.   JOURNAL OF IMMUNOLOGY

Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway

(2010) Min Lu et al.   EXPERIMENTAL HEMATOLOGY

Impaired interferon signaling is a common immune defect in human cancer

(2009) R. J. Critchley-Thorne et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA